ZA995297B - Polymorph of zopolrestat monohydrate. - Google Patents

Polymorph of zopolrestat monohydrate.

Info

Publication number
ZA995297B
ZA995297B ZA9905297A ZA995297A ZA995297B ZA 995297 B ZA995297 B ZA 995297B ZA 9905297 A ZA9905297 A ZA 9905297A ZA 995297 A ZA995297 A ZA 995297A ZA 995297 B ZA995297 B ZA 995297B
Authority
ZA
South Africa
Prior art keywords
polymorph
zopolrestat monohydrate
zopolrestat
monohydrate
Prior art date
Application number
ZA9905297A
Other languages
English (en)
Inventor
John Francis Lambert
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA995297B publication Critical patent/ZA995297B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9905297A 1998-08-21 1999-08-19 Polymorph of zopolrestat monohydrate. ZA995297B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
ZA995297B true ZA995297B (en) 2001-02-19

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9905297A ZA995297B (en) 1998-08-21 1999-08-19 Polymorph of zopolrestat monohydrate.

Country Status (31)

Country Link
US (1) US6159976A (ko)
EP (1) EP0982306A3 (ko)
JP (1) JP2000072769A (ko)
KR (1) KR20000017411A (ko)
CN (1) CN1245804A (ko)
AP (1) AP9901662A0 (ko)
AU (1) AU4453299A (ko)
BG (1) BG103674A (ko)
BR (1) BR9903873A (ko)
CA (1) CA2280590A1 (ko)
EA (1) EA199900675A3 (ko)
EE (1) EE9900385A (ko)
GT (1) GT199900137A (ko)
HR (1) HRP990259A2 (ko)
HU (1) HUP9902783A3 (ko)
ID (1) ID23307A (ko)
IL (1) IL131419A0 (ko)
IS (1) IS5155A (ko)
MA (1) MA26678A1 (ko)
NO (1) NO994027L (ko)
NZ (1) NZ337363A (ko)
OA (1) OA11150A (ko)
PA (1) PA8480601A1 (ko)
PE (1) PE20000993A1 (ko)
PL (1) PL335016A1 (ko)
SG (1) SG83147A1 (ko)
TN (1) TNSN99159A1 (ko)
TR (1) TR199901996A2 (ko)
UY (1) UY25668A1 (ko)
YU (1) YU39899A (ko)
ZA (1) ZA995297B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63796B1 (sr) 2010-07-16 2022-12-30 Univ Columbia Inhibitori aldoza reduktaze i njihova upotreba
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (en) * 2013-02-13 2014-08-21 Mylari Banavara L Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
DK3757107T3 (da) 2016-06-21 2023-11-27 Univ Columbia 4-oxo-3,4-dihydrothieno[3,4-d]pyridazinforbindelser som aldosereduktasehæmmere og metoder til anvendelse deraf
CA3071114A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
SG11202110590PA (en) 2019-04-01 2021-10-28 Applied Therapeutics Inc Inhibitors of aldose reductase
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CA3176768A1 (en) 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US6127367A (en) * 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
YU39899A (sh) 2002-12-10
EA199900675A3 (ru) 2000-06-26
JP2000072769A (ja) 2000-03-07
SG83147A1 (en) 2001-09-18
BR9903873A (pt) 2000-09-19
NO994027D0 (no) 1999-08-20
IL131419A0 (en) 2001-01-28
HRP990259A2 (en) 2000-06-30
HU9902783D0 (en) 1999-10-28
TR199901996A2 (xx) 2000-03-21
EE9900385A (et) 2000-04-17
PE20000993A1 (es) 2000-10-04
HUP9902783A2 (hu) 2000-12-28
GT199900137A (es) 2001-02-09
CA2280590A1 (en) 2000-02-21
PA8480601A1 (es) 2000-09-29
AP9901662A0 (en) 1999-09-30
AU4453299A (en) 2000-03-09
CN1245804A (zh) 2000-03-01
US6159976A (en) 2000-12-12
HUP9902783A3 (en) 2001-01-29
ID23307A (id) 2000-04-05
KR20000017411A (ko) 2000-03-25
EP0982306A2 (en) 2000-03-01
OA11150A (en) 2003-04-16
BG103674A (en) 2000-03-31
UY25668A1 (es) 2001-08-27
EP0982306A3 (en) 2000-07-05
PL335016A1 (en) 2000-02-28
TNSN99159A1 (fr) 2005-11-10
NZ337363A (en) 2001-01-26
EA199900675A2 (ru) 2000-02-28
IS5155A (is) 2000-02-22
MA26678A1 (fr) 2004-12-20
NO994027L (no) 2000-02-22

Similar Documents

Publication Publication Date Title
PL345589A1 (en) β-CARBOLINE COMPOUNDS
PL341647A1 (en) Novel derivatives of erythromycin
IL141433A0 (en) Crystalline forms of eto2c-ch2- (r) cgl-aze-pab-oh
HUP0101753A3 (en) Boring-tool
SI1097148T1 (en) Polymorph of ritonavir
AU1393799A (en) Cooling of stored water
GB9805348D0 (en) Compound
HU9902062D0 (en) Compound liquor
ZA995297B (en) Polymorph of zopolrestat monohydrate.
EP0991647A4 (en) EPROSARTANE MONOHYDRATE
HK1027110A1 (en) Production of avermectin compounds.
ZA200007084B (en) Novel salts of N-tert-butylhydroxylamine.
GB9808268D0 (en) Compound
EP1129193A4 (en) CHEMOKIN BETA-7
IL142218A0 (en) PROCESS FOR THE PREPARATION OF (-) -α- DIFLUORMETHYLORNITHINE MONOHYDROCHLORIDE MONOHYDRATE
ZA99531B (en) Production of heptafluoropropane.
ZA200002826B (en) Method of micorbial granule formation.
HU9900545D0 (en) Gaviota variety of strawberry (fragaria l.)
HU9900528D0 (en) Diamante variety of strawberry (fragaria l.)
GB9823175D0 (en) Compound
TW410774U (en) Improved structure of line mandrel
GB9919911D0 (en) Single hole water cooler
SI1107980T1 (en) CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH
TW357888U (en) Improvement of filter-drier
GB9914021D0 (en) Chemical compound